As diabetes and hypertension coexist, the use of empagliflozin (perhaps other SGLT2 inhibitors) in this high-risk diabetic population may complement conventional antihypertensive therapy to potentially reduce the overall risk of adverse cardiovascular events such as heart attack and stroke. This evidence concerns the gene SLC5A2 and Hypertension.